Gérard Claire, Fagnoni Philippe, Vienot Angélique, Borg Christophe, Limat Samuel, Daval Franck, Calais François, Vardanega Julie, Jary Marine, Nerich Virginie
Department of Pharmacy, University Hospital of Besançon, Besançon, France; INSERM UMR 1098, University of Bourgogne - Franche-Comté, Besançon, France.
Department of Pharmacy, University Hospital of Dijon, Dijon, France; INSERM UMR 866, University of Bourgogne - Franche-Comté, Dijon, France; EPICAD LNC UMR 1231, University of Bourgogne - Franche-Comté, Dijon, France.
Eur J Cancer. 2017 Nov;86:207-216. doi: 10.1016/j.ejca.2017.08.035. Epub 2017 Oct 9.
The economic evaluation (EE) of healthcare interventions has become a necessity. However, high quality needs to be ensured in order to achieve validated results and help making informed decisions. Thus, the objective of the present study was to systematically identify and review published pancreatic ductal adenocarcinoma-related EEs and to assess their quality.
Systematic literature research was conducted in PubMed and Cochrane to identify published EEs between 2000 and 2015. The quality of each selected EE was assessed by two independent reviewers, using the Drummond's checklist.
Our systematic review was based on 32 EEs and showed a wide variety of methodological approaches, including different perspectives, time horizon, and cost effectiveness analyses. Nearly two-thirds of EEs are full EEs (n = 21), and about one-third of EEs had a Drummond score ≥7, synonymous with 'high quality'. Close to 50% of full EEs had a Drummond score ≥7, whereas all of partial EEs had a Drummond score <7 (n = 11).
Over the past 15 years, a lot of interest has been evinced over the EE of pancreatic ductal adenocarcinoma (PDAC) and its direct impact on therapeutic advances in PDAC. To provide a framework for health care decision-making, to facilitate transferability and to lend credibility to health EEs, their quality must be improved. For the last 4 years, a tendency towards a quality improvement of these studies has been observed, probably coupled with a context of rational decision-making in health care, a better and wider spread of recommendations and thus, medical practitioners' full endorsement.
医疗保健干预措施的经济评估（EE）已成为必要之举。然而，为了获得有效的结果并有助于做出明智的决策，需要确保高质量。因此，本研究的目的是系统地识别和综述已发表的与胰腺导管腺癌相关的经济评估，并评估其质量。
在PubMed和Cochrane上进行系统的文献研究，以识别2000年至2015年间发表的经济评估。由两名独立的评审员使用德拉蒙德清单对每项选定的经济评估的质量进行评估。
我们的系统综述基于32项经济评估，显示出各种各样的方法学途径，包括不同的视角、时间范围和成本效益分析。近三分之二的经济评估是全面的经济评估（n = 21），约三分之一的经济评估的德拉蒙德评分≥7，等同于“高质量”。近50%的全面经济评估的德拉蒙德评分≥7，而所有部分经济评估的德拉蒙德评分<7（n = 11）。
在过去15年中，人们对胰腺导管腺癌（PDAC）的经济评估及其对PDAC治疗进展的直接影响表现出了浓厚的兴趣。为了提供医疗保健决策的框架，促进可转移性并增强健康经济评估的可信度，必须提高其质量。在过去4年中，已观察到这些研究有质量改进的趋势，这可能与医疗保健中的理性决策背景、建议的更好更广泛传播以及因此医生的完全认可有关。
